BioSpace News Archive

Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the presentation of preclinical data for its first VDC product candidate, AU‑011.

Invitae, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2022.

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the BofA Securities Healthcare Conference at 10:00 a.m. PT on Tuesday, May 10, 2022.

Kezar Life Sciences, Inc. announced topline results from the PRESIDIO Phase 2 clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis.

Ocular Therapeutix, Inc. announced two scientific presentations at the American Society of Gene & Cell Therapy 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually.

Varex Imaging Corporation announced its unaudited financial results for the second quarter of fiscal year 2022.

Health Canada recently authorized the Dolphin Vagal Nerve Stimulator by the Center for Pain and Stress Research to treat symptoms in patients with COVID-19 Long Haul (long haulers).

Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products to proceed with a new clinical study in France.

The global facial injectable market is expected to reach the value of US$ 28.13 Billion by2030 and is predicted to record a growth rate of 9.7% from 2021-2030.

The global elderly and disabled assistive devices market size is expected to surpass around US$ 34.18 billion by 2030 from US$ 22.07 billion in 2021 and expanding growth at a CAGR of 5% from 2022 to 2030.